Validation of the Oncoliq Test for the Early Detection of Breast Cancer.

Plain-language summary

This study aims to validate the Oncoliq test, which uses a blood sample, for the early detection of breast cancer. It enrolls women aged 40 to 70 diagnosed with breast cancer at any stage, as well as women aged 50 to 70 with no history of cancer as a control group. It is a study with no assigned phase and is currently recruiting participants.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Recruiting

Sponsor

Oncoliq US Inc

Intervention

Peripheral blood draw

Start date

10/17/2025

Estimated completion

2/28/2026

Countries

Argentina

Related genes

Locations

• Buenos Aires, Argentina

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

Group 1 - Breast Cancer:

Age between 40 and 70 years Diagnosis of breast cancer at any stage No prior surgical treatment No prior antineoplastic treatment Pathology report available at the time of enrollment Signed informed consent

Group 2 - No Cancer (Control):

Age between 50 and 70 years No diagnosis or personal history of any type of cancer Digital mammography and breast ultrasound showing no breast pathology (BI-RADS 1 or 2) Signed informed consent

Exclusion Criteria:

Refusal to sign the informed consent Communication issues that hinder understanding (hearing loss, blindness, intellectual disability, or dementia) Venipuncture for blood collection impracticable or posing a risk Personal history of previous cancer